ALNA - First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment
- Allena Pharmaceuticals ( NASDAQ: ALNA ) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout patients with stage 2 and stage 3 chronic kidney disease (CKD).
- ALNA is planning to enroll up to four cohorts in the mid-stage trial, called Study 202, with each cohort consisting of up to 12 patients.
- Cohort A of the trial has enrolled seven patients with stage 2, or mild CKD, and cohort B has enrolled 12 patients with stage 3, or moderate CKD.
- ALNA said safety and efficacy data from the first two cohorts of the study are expected to be available later this quarter.
- ALNA stock +1.5% to $0.15 in morning trading.
For further details see:
First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment